公开(公告)号：WO2008019346A2

公开(公告)日：2008-02-14

申请号：PCT/US2007075292

申请日：2007-08-06

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  CHILDREN S HOSPITAL OF PITTSBU ,  BROWN LARRY R ,  GIANNOUKAKIS NICK ,  GILLIS KIMBERLY A

Inventor： BROWN LARRY R ,  GIANNOUKAKIS NICK ,  GILLIS KIMBERLY A

IPC: A61K31/7088 ,  A61K38/28 ,  A61P3/10 ,  A61P37/00

CPC classification number: A61K31/7088 ,  A61K9/0024 ,  A61K9/1641 ,  A61K9/19 ,  A61K38/28 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2320/32 ,  A61K2300/00

Abstract: AS-oIigonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract translation: 为了诱导树突细胞耐受，特别是在非肥胖 - 糖尿病（NOD）小鼠模型中，AS-oI核苷酸以微球形式递送。 微球体掺入反义（AS）寡核苷酸。 一个过程包括使用反义方法在体内NOD小鼠中逆转自身免疫性糖尿病状况。 靶向寡核苷酸以结合初级转录物CD40，CD80，CD86及其组合。

公开(公告)号：EP1335661A4

公开(公告)日：2007-08-22

申请号：EP01987562

申请日：2001-10-25

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： BROWN LARRY R

IPC: A61K9/00 ,  A61K9/16 ,  A61K31/715 ,  A61K9/14

CPC classification number: A61K31/715 ,  A61K9/0073 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1694

公开(公告)号：WO2010022320A3

公开(公告)日：2010-08-19

申请号：PCT/US2009054595

申请日：2009-08-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  YANG GUOHAN ,  HAI TON THAT ,  MELNICK BENNETT ,  SAUNDERS PAUL ,  JIANG CONG ,  QUINN CATHERINE ,  LI JIE ,  AMBROISE AROUNAGUIRY ,  BROWN LARRY R

Inventor： YANG GUOHAN ,  HAI TON THAT ,  MELNICK BENNETT ,  SAUNDERS PAUL ,  JIANG CONG ,  QUINN CATHERINE ,  LI JIE ,  AMBROISE AROUNAGUIRY ,  BROWN LARRY R

IPC: A61K47/48 ,  A61P7/00

CPC classification number: A61K47/48215 ,  A61K31/405 ,  A61K47/60

Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.

Abstract translation: 本发明涉及聚合衍生物，其可以与含氨基的药物缀合以改善其体内特性。 随后可以释放聚合物衍生物以产生其天然形式的药物。 描述了制备和使用这些聚合物衍生物和药物偶联物的方法。

公开(公告)号：WO2008131129A3

公开(公告)日：2009-05-14

申请号：PCT/US2008060669

申请日：2008-04-17

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  BROWN LARRY R ,  GILLIS KIMBERLY A ,  GALLO MICHAEL

Inventor： BROWN LARRY R ,  GILLIS KIMBERLY A ,  GALLO MICHAEL

IPC: A61K9/12 ,  A61K9/16

CPC classification number: A61K9/50 ,  A61K9/0075 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1688 ,  A61K9/5031 ,  A61K38/28

Abstract: The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells.

Abstract translation: 本公开内容涉及微粒组合物，其中微粒由核酸和非聚合阳离子制成，其适用于向湿或水性靶位置（例如，肺组织）施用，其中基本上球形的核酸微粒 通过溶解释放核酸，允许释放的核酸与靶细胞自由相互作用。

公开(公告)号：WO2008130803A2

公开(公告)日：2008-10-30

申请号：PCT/US2008059094

申请日：2008-04-02

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  BROWN LARRY R ,  MCGEEHAN JOHN K ,  YUANXI QIN ,  RASHBA-STEP JULIA ,  SCOTT TERRENCE L

Inventor： BROWN LARRY R ,  MCGEEHAN JOHN K ,  YUANXI QIN ,  RASHBA-STEP JULIA ,  SCOTT TERRENCE L

IPC: A61K9/72 ,  A61K38/28

CPC classification number: A61K9/0075 ,  A61K38/28

Abstract: Compositions of spherical insulin particles having improved pulmonary application potentials and methods of forming and using these compositions are disclosed in the present application. In one clinical trial with 30 healthy male human subjects, no coughing was observed upon a single pulmonary administration of the spherical insulin particles at an insulin dose of 6.5 mg, nor during the 10-hour post dosing period.

Abstract translation: 在本申请中公开了具有改善的肺部施用电位的球形胰岛素颗粒的组合物以及形成和使用这些组合物的方法。 在30名健康雄性人类受试者的一项临床试验中，在胰岛素剂量为6.5mg的单次肺部施用球素胰岛素颗粒时，也不在给药后10小时期间观察不到咳嗽。

公开(公告)号：WO2008073642A2

公开(公告)日：2008-06-19

申请号：PCT/US2007083952

申请日：2007-11-07

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  BROWN LARRY R ,  YANG MARK X ,  O'CONNELL ED

Inventor： BROWN LARRY R ,  YANG MARK X ,  O'CONNELL ED

IPC: A61K39/395 ,  A61K9/14 ,  A61K38/28

CPC classification number: A61K9/0019 ,  A61K9/10 ,  A61K9/1688 ,  A61K38/28 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K2317/24

Abstract: The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical particles that are substantially amorphous or non-crystalline and are injectable through fine bore needles at high concentrations. The particles exhibit the pharmacokinetic and pharmacodynamic properties of the active agent. The disclosure has special application for higher molecular weight proteins such as antibodies.

Abstract translation: 本公开涉及制备和组合活性剂颗粒的小组合物的方法的组合物。 根据生产方法，将活性剂溶解在含有溶解的相分离增强剂（PSEA）的水性或水性混溶性溶剂中以形成单一液相中的溶液。 使溶液经受液 - 固相分离以使活性剂形成基本上无定形或非结晶的小球形颗粒，并且可通过高浓度的细孔针注射。 颗粒表现出活性剂的药代动力学和药效学性质。 本公开对高分子量蛋白质例如抗体具有特殊的应用。

公开(公告)号：EP2086572A4

公开(公告)日：2013-05-29

申请号：EP07871397

申请日：2007-11-07

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： BROWN LARRY R ,  YANG MARK X ,  O'CONNELL ED

IPC: A61K9/10 ,  A61K9/14

CPC classification number: A61K9/0019 ,  A61K9/10 ,  A61K9/1688 ,  A61K38/28 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K2317/24

公开(公告)号：EP2056883A4

公开(公告)日：2010-10-27

申请号：EP07813820

申请日：2007-08-06

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  UNIV PITTSBURGH

Inventor： BROWN LARRY R ,  GIANNOUKAKIS NICK ,  GILLIS KIMBERLY A

IPC: C12N15/11 ,  A61K9/16 ,  A61K9/50 ,  A61K31/713

CPC classification number: A61K31/7088 ,  A61K9/0024 ,  A61K9/1641 ,  A61K9/19 ,  A61K38/28 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2320/32 ,  A61K2300/00

公开(公告)号：DK2334394T3

公开(公告)日：2014-01-13

申请号：DK09791748

申请日：2009-08-20

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： PIRAN URI ,  MEHR EUGENE ,  BROWN LARRY R ,  MCGEEHAN JOHN K ,  O'CONNELL ED

IPC: B01D11/02 ,  A61K9/16 ,  B01J13/02

公开(公告)号：AU2007281737B2

公开(公告)日：2013-09-19

申请号：AU2007281737

申请日：2007-08-06

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT ,  UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION

Inventor： BROWN LARRY R ,  GILLIS KIMBERLY A ,  GIANNOUKAKIS NICK

IPC: A61K48/00

Abstract: AS-oIigonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.